Kornimate/medical-research-clean huggingface dataset:
diaphragmatic ultrasound and weaning after lung transplant.

Conditions: Diaphragm; Diaphragm Disease; Diaphragm Issues; Weakness, Muscle

Summary: the prevalence and adverse effect of diaphragm dysfunction (dd) after bilateral-lung transplant (lt) are still unclear, despite a well-known negative impact on weaning and outcome in other cohorts of critically ill and surgical patients. objects: the primary aim is investigating the prevalence of dd, assessed using point-of-care ultrasound and defined as diaphragm thickening fraction (tfdi) \< 29%, at the first weaning trial after lt. secondary aims are investigating the impact of dd on weaning (defined success or failure according to pre-defined criteria, neuroventilatory efficiency (eadi or nve), perioperative (14-day) pneumonia, icu length of stay (los), in-hospital mortality, and identifying potential risk factors for dd. moreover, we aim to study the correlation between tfdi versus eadi/nve and the rapid shallow breathing index (rsbi), respectively.

this is a prospective observational cohort study, approved by the institutional ethical committee of padua (reference number aop2722). written informed consent was obtained from each patient during the preoperative visit. all consecutive lt patients admitted to the intensive care unit of the university hospital of padua were screened. adult patients undergoing bilateral lt, not requiring invasive mechanical ventilation before surgery, were eligible for inclusion in the study only when they met the predefined 'readiness-to-wean' criteria on daily screening and were therefore deemed ready to undergone a first 30-min weaning trial. exclusion criteria were: presence of neuromuscular blockers in the previous 12 hours, lack of ultrasound acoustic window, decline to participate, right hemi-diaphragmatic palsy due to surgical sacrifice of right phrenic nerve, duplicated patients.

Eligibility criteria:
inclusion criteria: * adult patients * bilateral lt * absent invasive mechanical ventilation before surgery * fullfilling 'readiness-to-wean' criteria on daily screening (and therefore deemed ready to undergone a first 30-min weaning trial) exclusion criteria: * presence of neuromuscular blockers in the previous 12 hours * lack of ultrasound acoustic window * decline to participate * right hemi-diaphragmatic palsy due to surgical sacrifice of right phrenic nerve * duplicated patients.

Keywords: bilateral lung transplant diaphragmatic dysfunction
questionnaire and tissue banking for multiple myeloma, waldenstrom macroglobulinemia and related disorders

Conditions: Multiple Myeloma; Waldenstrom's Macroglobulinemia; Smoldering Multiple Myeloma; Lymphoblastic Lymphoma

Summary: the purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with multiple myeloma (mm), waldenstrom's macroglobulinemia (wm), smoldering mm, and other lymphoplasmacytic lymphomas (lpl) including but not limited to mgus and igg or iga lpl. these samples will become part of a tissue bank and will be used in ongoing studies to find out more about the causes and biology of mm, wm and lpl; to identify what factors result in normal cells becoming cancer; to determine how to improve treatment options; to study how the immune system identifies abnormal cells; and to evaluate the immune function in these diseases. the investigators will also study the tumor cells at the level of the participant's genes to develop treatment strategies as well as to better understand how biologic differences affect patient outcomes.

* participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. * participants will then receive instructions for the tissue banking procedure, which involves donating bone marrow and blood samples. these will be collected only at times when necessary clinical bone marrow samples are obtained and will not require an extra visit to the doctor. * the investigators are also requesting permission to collect medical information from the participant's record and link this information to the specimens so that we may better understand the participant's response to treatment. for samples obtained prior to beginning therapy, this information might allow us to develop new ways of predicting response to therapy. the investigators are also requesting permission to store samples of blood and bone marrow to establish a tissue bank for future research to these diseases. these samples will be de-identified; any of the participant's personal health information identifiers will be removed. * the tumor sample may be obtained at diagnosis, during treatment and/or as the time of relapse. the timing of sample collection will coincide with other bone marrow tests required to assess the response to therapy or any other clinical purpose.

Eligibility criteria:
inclusion criteria: * any individual diagnosed with multiple myeloma, waldenstrom macroglobulinemia, mgus, smoldering mm or other lymphoplasmacytic lymphomas * signed informed consent * 18 years of age or older

Keywords: waldenstrom myeloma smoldering lymphoma mgus distinct b-cell lymphoproliferative disorder
visceral osteopathy in functional constipation

Conditions: Functional Constipation

Summary: it is a functional bowel disease characterized by excessive straining during defecation, infrequent defecation, and the feeling of incomplete evacuation. there are very few studies investigating the incidence and prevalence of functional constipation.non-pharmacological treatment methods, including lifestyle changes, are primarily recommended for the treatment of constipation. the aim of the study is to examine the effects of visceral osteopathic approaches on individuals diagnosed with functional constipation and compare them with conventional methods.

non-pharmacological treatment methods, including lifestyle changes, are primarily recommended for the treatment of constipation. in cases where success is not achieved with this method, pharmacological agents, biofeedback and surgical treatment methods can be applied depending on the severity of constipation. lifestyle changes include increasing fiber and fluid intake and regular physical activity osteopathic manual therapy (omt) is the examination and treatment of the function of the neuromusculoskeletal system anatomy using non-invasive, generally safe manual techniques to improve functional body mechanics such as joint range of motion, muscle tone, circulation, body fluid pressures and exchanges, and nerve impulses. omt is used for autonomic system regulation, balancing pelvic muscle tone, increasing gastrointestinal motility, preventing myofascial limitations and increasing the pump effect of the diaphragm (5,6). the positive effects of omt on the microbiome are available in the literature. alternative treatments are needed because the costs of combating constipation are high. non-invasive interventions are especially gaining importance.

Eligibility criteria:
inclusion criteria: * volunteer individuals aged 18 and over * clinical diagnosis with functional constipation based on roma iv criteria exclusion criteria: * clinical diagnosis of a gastrointestinal disease other than constipation, * undergone abdominal surgery in the last 6 months, * having abdominal aortic aneurysm, acute rectal bleeding, malignant mass in the gis, * pregnancy or suspected of pregnancy, * cliniclal diagnosis of neurological disease that may cause constipation, * expreinced unexplained fever, individuals with night sweats and weight loss

Keywords: functional constipatiton visceral osteopathy
inflammation and obesity-associated disease

Conditions: Obesity; Inflammation; Kidney Disease; Liver Disease; Metabolic Syndrome; Cardiometabolic Syndrome; Fibrosis

Summary: visceral obesity and adipose inflammation is considered a driving force of obesity-related systemic disease, e.g. cardiometabolic disease, liver cirrhosis and chronic kidney disease (ckd). inflammatory resolution is actively regulated by specialized pro-resolving mediators (spms), including the endogenous eicosanoid lxa4. impairment of spms may underlie development of obesity-related pathology.we hypothesize that obese patients who develop obesity-related disease do so because they suffer from impaired endogenous production of pro-resolving lipids. this will result in aggravated adipose inflammation and fibrosis, which contribute to the systemic pathologies. we thus wish to investigate adipose inflammation and the pro-resolving lipid profile of obese subjects with and without obesity associated metabolic disease. we also aim to investigate whether lxa4, lxb4 and other anti-inflammatory agents (such as aicar) can alter the phenotype of human adipose macrophages in ex vivo tissue culture. we also investigate basic pathways in inflammatory regulation and obesity related cardiometabolic disease.


Eligibility criteria:
inclusion criteria: * obese bmi 35-55 kg/m2 * lean bmi 18.5-24.9 exclusion criteria: * medical treatment with nsaids, corticosteroid treatment, immune-suppressants. * other: smoking, alcohol abuse.
long-term study of epiduo in patients with moderate to severe acne

Conditions: Acne Vulgaris

Summary: this observational study is designed to assess the long-term efficacy and safety of epiduo (alone or in combination with other drugs) under daily clinical practice conditions in patients with moderate to severe inflammatory acne. in addition, the effect of epiduo on quality of life and patient adherence will be assessed under marketed conditions.

this observational study is designed to assess the long-term efficacy and safety of epiduo under daily clinical practice conditions. the study includes patients of all ages with moderate to severe inflammatory acne, taking epiduo alone or in combination with other drugs. in addition, the effect of epiduo alone or in combination with other drugs on quality of life and patient adherence will be assessed under marketed conditions. the observational study is designed as a multicentre study, covering all parts of germany. participating investigators are dermatologists with an adequate patient pool of acne patients. the observation time per patient will be 9 months. an interim and final examination with subsequent documentation are designated to be performed about 3 and 9 months after the start of treatment, respectively.

Eligibility criteria:
inclusion criteria: * the patient has been diagnosed with moderate to severe inflammatory acne (leeds grade 4-12) * topical therapy of acne with epiduo is indicated, the decision about treating the patient with epiduo has been made independently from this study exclusion criteria: * use of epiduo within 3 months prior to inclusion * pregnancy or breastfeeding * acne inversa * acne with preferential manifestation of microcysts, macrocysts and macrocomedones * hypersensitivity to the drug or any of its ingredients * if applicable, other restrictions outlined in the spc of epiduo

Keywords: acne epiduo adapalene/ benzoyl peroxide
real world study on the efficacy and safety of apremilast in chinese patients with moderate to severe plaque psoriasis, a multi center, prospective, observational trial（react）

Conditions: Psoriasis

Summary: this is a multicenter, one-arm, prospective, observational study，intended to assess evaluation of efficacy and safety of apremilast in chinese patients with moderate-to-severe plaque psoriasis。during this study, it is expected to collect data at at baseline and weeks 2, 6, 10, 16, and 20 after treatment。


Eligibility criteria:
inclusion criteria: * males or females, ≥ 18 years of age at the time of signing the informed consent document； * patients with moderate-to-severe plaque psoriasis：simultaneously meet (1)and (2): (1)pasi≥ 3；(2) dlqi ≥ 6； * subject is a candidate for phototherapy and/or systemic therapy * patients who wish to be treated with apremilast and sign the informed consent exclusion criteria: * allergy to apremilast or any component of the study drug； * use of phototherapy within 4 weeks prior to randomization；use of systemic drugs or biologic agents within 4 half-life periods prior to randomization；patients with inadequate response or intolerance to previous systemic therapy do not need to consider drug washout； * currently using potent cytochrome p450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin, etc.)； * history of substance abuse, suicide attempts, or mental illness； * patients who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period； * pustular type, erythroderma type and other psoriasis patients； * other circumstances that investigators don't consider appropriate to include.

Keywords: apremilast otazla real world study
limbs range of motion exercises along with chest physical therapy after correction of congenital heart diseases in icu

Conditions: Congenital Heart Disease

Summary: 1. to determine the effect of limb roms along with chest physical therapy on cardiopulmonary parameters after correction of congenital heart diseases in icu 2. to determine the response of inotropic drug in relation to limb roms after correction of congenital heart diseases in icu


Eligibility criteria:
inclusion criteria: * patients below the age 5 years old that underwent congenital heart surgery. exclusion criteria: * contraindications for exercise, mental retardation, unstable hemodynamics
study of omnigraft in simultaneous pancreas kidney recipients

Conditions: Kidney Transplant; Complications; Pancreas Disease

Summary: the purpose of this research is learn about how omnigraf works in kidney pancreas transplant patients. also, to analyze the performance characteristics of omnigraftm (trugraf gene expression profiling (gep) and t cell receptor alpha constant (trac) dd-cfdna) in a population of simultaneous kidney pancreas transplants as a part of routine surveillance, as well as a part of the workup for patients clinically suspected to have rejection of the kidney and/or pancreas.


Eligibility criteria:
inclusion criteria: 1. male or female adult (≥18 years old) with a history of simultaneous pancreas kidney transplant between 3 months and 1 year prior to enrollment (cohort 1) or at the time of presentation for "for-cause" biopsy 2. adults able to consent 3. bladder or enteric drained 4. type 1 or type 2 dm exclusion criteria: 1. recipient of an organ transplant other than a simultaneous pancreas kidney transplant 2. known to be pregnant 3. known to be infected with human immunodeficiency virus with actively replicating hiv virus 4. active bk viremia with \>100,000 copies or biopsy proven bk nephropathy 5. participation in other biomarker studies 6. pancreas transplant alone 7. re-transplantation, unless both organs have been removed prior to or at the time of the retransplant procedure.
magestic trial: mirna in detecting active germ cell tumors in early suspected and metastatic disease trial

Conditions: Malignant Testicular Germ Cell Tumor

Summary: this study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.

primary objective: i. to measure the accuracy of the blood-based biomarker mirna-371 to predict pre-operatively the presence of active germ cell malignancy. outline: this is an observational study. patients undergo blood sample collection during screening and throughout the study. patients whose screening blood samples show elevated mirna-371 proceed to standard rplnd surgery. patients whose screening blood samples show normal levels of mirna-371 undergo standard surveillance followed by standard rplnd surgery at the time of elevated mirna-371 levels. patients may also have their medical records reviewed.

Eligibility criteria:
inclusion criteria: * primary tumor excised by radical inguinal orchiectomy and pathology consistent with gct (seminoma or nsgct) * clinical stage of patient is either: * stage i pure seminoma or stage i pure seminoma with isolated retroperitoneal relapse or stage iia/b pure seminoma * stage i nsgct or stage i nsgct with isolated retroperitoneal relapse or stage iia/b nsgct * suspected retroperitoneal disease: lymphadenopathy in the retroperitoneum with no lymph node \>3 cm in greatest dimension with no more than 2 nodes enlarged * axial imaging within 6 weeks of enrollment * chest imaging (x-ray, ct or mri) negative for metastasis within 6 weeks of enrollment * mirna-371 level drawn at any timepoint after orchiectomy * retroperitoneal lymphadenopathy must be within an rplnd template * biopsy of lymph node is not required, though if biopsy of the retroperitoneal node(s) was obtained, pathology must be consistent with gct * serum alpha feto protein (afp), β-human chorionic gonadotropin (hcg), lactate dehydrogenase (ldh) - per the local laboratory assay \<1.5xlower normal level within 30 days of enrollment * age ≥ 16 years * eastern cooperative oncology group (ecog) performance status ≤2 * ability to understand and the willingness to sign a written informed consent exclusion criteria: * second primary malignancy * history of receiving chemotherapy or radiotherapy * patients receiving any other investigational agent (s) * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
pulmonary artery doppler in preeclamptic mothers

Conditions: Pulmonary Artery Doppler

Summary: evaluation of pulmonary artery doppler parameters in fetuses of mothers with severe preeclampsia

preclampsia (pe) represent a major concern in public health, affecting 2-8% of all pregnancies and considered one of the leading causes of perinatal morbidity and mortality. fetal growth restriction (fgr) ia also a common health problem affecting about 5-10% of all pregnancies and commonly associates with preeclampsia . it is estimated that 20% of cases of pe present with fgr and about 50% of early-onset fgr cases will eventually coexist with pe. preeclampsia affects about 5% of pregnancies and hypertensive disorders of pregnancy cause over 60,000 maternal fatalities each year around the world .the decision to deliver a woman with severe pre-eclampsia that is far from the term \[mid-trimester\] is difficult for the obstetrician.in most cases of highly premature pre-eclamptic gestation, certain institutions propose continuing pregnancy until one of the following occurs development of fetal lung maturity, development of fetal or maternal discomfort, or accomplishment of gestational age of 34 to 36-week of gestation . numerous tests have been developed in an attempt to identify if fetal lung maturation has reached a level sufficient to prevent the development of fetal rds. these tests are based on four core themes: biochemical testing for active surfactant components, biophysical testing for surfactant functionality, physical testing of amniotic fluid opacity, and ultrasound examination of the fetuses and their tissues . neonatal rds has been predicted using fetal pulmonary artery doppler. kim and colleagues discovered that a high pat/et was linked to newborn rds .the development of rds in preterm newborns is linked to an increased acceleration time to ejection time \[at/et\] ratio in the fetal pulmonary artery .

Eligibility criteria:
inclusion criteria: * preeclampsia patients pregnant 28 -37 weeks exclusion criteria: * fetal death congenital fetal anomalies fetal cardiac arrhythmia

Keywords: pulmonary doppler preeclampsia
choice architecture and mailed colorectal cancer screening outreach in a community health setting

Conditions: Colorectal Cancer

Summary: this is a 3-arm randomized trial aimed at increasing rates of participation in colorectal cancer (crc) screening by outreach to patients' homes using choice architecture informed by behavioral science principles.

the investigators will evaluate the effectiveness of mailed outreach with choice between colonoscopy and fit, and fit alone, as compared to colonoscopy alone in increasing crc screening rates.

Eligibility criteria:
inclusion criteria: 1. at least 1 visit with chdc in the past 2 years 2. not up to date on crc screening (no evidence of colonoscopy in the last 10 years, sigmoidoscopy in the last 5 years, or stool testing in the past 12 months) exclusion criteria: 1. history of crc or polyps 2. significant family history of crc 3. history of inflammatory bowel disease or ulcerative colitis 4. history of colectomy 5. history of metastatic cancer 6. current use of medication assisted therapy (mat)

Keywords: screening prevention colonoscopy stool testing
efficacy and safety of dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib

Conditions: Gastrointestinal Stromal Tumors

Summary: the purpose of this study is to evaluate the efficacy and safety of dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib


Eligibility criteria:
inclusion criteria: * histologically confirmed gist of any anatomical location, which is 1) unresectable and/ or metastatic with documented disease progression while on therapy with imatinib or 2) surgically removed localized gist, recurrent on adjuvant imatinib or recurrent within the first 3 months after discontinuation of adjuvant imatinib or 3) patients with unresectable and/or metastatic gist intolerant to imatinib * positive immunohistochemical staining for c-kit (cd117); or negative staining for kit, but with either positive staining for dog1 or an identified mutation of kit or pdgfra gene * documented disease progression according to recist (version 1.1) on prior therapy with imatinib at a dose of at least 400mg/day or patients with unresectable and/or metastatic gist who are intolerant to imatinib * at least one measurable gist lesion according to recist (version 1.1). * adequate bone marrow, liver and renal function exclusion criteria: * patients who have received any other tyrosine-kinase inhibitor but imatinib for gist * patients who received cytotoxic drugs ≤ 4 weeks prior to starting dovitinib (tki258) * patients who are treated or planned to be treated concomitantly with other cytotoxic or antineoplastic treatments, such as chemotherapy, immunotherapy, biological response modifiers, or radiotherapy * patients with another primary malignancy within 3 years prior to starting the study drug * patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) ≤ 4 weeks prior to starting dovitinib (tki258) or who have not recovered from the adverse effects of such therapy * patients with a history of pulmonary embolism (pe), or untreated deep venous thrombosis (dvt) within the past 6 months * patients with impaired cardiac function or clinically significant cardiac diseases * patients with impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of dovitinib * patients with prior complete gastrectomy * patients with brain metastasis or history of brain metastasis * patients who are currently receiving anticoagulation treatment with therapeutic doses of warfarin or equivalent anticoagulant * pregnant or breast-feeding women other protocol-defined inclusion/exclusion criteria may apply.

Keywords: gist dovitinib